Search research articles
Contact Us
Filters
Showing results (141-150 of 211) with videos related to
Page
of 22
Sort By:
Haematologica
|
July 10, 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
The Lancet. Haematology
|
March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood Cancer Journal
|
April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Adrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Blood Advances
|
December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Page
of 22
Search research articles
Search
Showing results (141-150 of 211) with videos related to
Sort By:
Page
of 22
Haematologica
|
July 10, 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
The Lancet. Haematology
|
March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood Cancer Journal
|
April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Adrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Blood Advances
|
December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Page
of 22